Passive immunization during pregnancy for congenital cytomegalovirus infection

New England Journal of Medicine

Volumn 353, Issue 13, 2005, Pages 1350-1362

  Nigro, Giovanni ^a,c   Adler, Stuart P ^b   La Torre, Renato ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; VIRUS DNA;

ADULT; AMNIOCENTESIS; AMNION FLUID; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DELIVERY; DISABILITY; DRUG SAFETY; FEMALE; GESTATIONAL AGE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PASSIVE IMMUNIZATION; PREGNANCY; PRIORITY JOURNAL; RISK REDUCTION;

EID: 25444434851     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa043337     Document Type: Article

References (31)

1. Stagno S. Cytomegalovirus. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. 5th ed. Philadelphia: W.B. Saunders, 2001:389-424.
2. Alford CA, Stagno S, Pass RF, Britt WJ. Congenital and perinatal cytomegalovirus infections. Rev Infect Dis 1990;12:Suppl 7:S745-S753.
3. Stagno S, Whitley RJ. Herpesvirus infections of pregnancy. I. Cytomegalovirus and Epstein-Barr virus infections. N Engl J Med 1985;313:1270-4.
4. Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus, and clinical outcome. JAMA 1986;256:1904-8.
5. Nigro G, La Torre R, Anceschi MM, Mazzocco M, Cosmi EV. Hyperimmunoglobulin therapy for a twin fetus with cytomegalovirus infection and growth restriction. Am J Obstet Gynecol 1999;180:1222-6.
6. Volpe JJ. Neurology of the newborn. 4th ed. Philadelphia: W.B. Saunders, 2001.
7. Lubchenko LO. Assessment of gestational age and development of birth. Pediatr Clin North Am 1970;17:125-45.
8. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317:1049-54.
9. Ballow M. Mechanisms of action of intravenous immune serum globulin therapy. Pediatr Infect Dis J 1994;13:806-11.
10. Clark AL, Gall SA. Clinical uses of intravenous immunoglobulin in pregnancy. Am J Obstet Gynecol 1997;176:241-53.
11. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000;13:602-14.
12. Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000;47:57-77.
13. Nigro G, Mazzocco M, Anceschi MM, La Torre R, Antonelli G, Cosmi EV. Prenatal diagnosis of fetal cytomegalovirus infection following primary or recurrent maternal infection. Obstet Gynecol 1999;94:909-14.
14. Grangeot-Keros L, Mayaux MJ, Lebon P, et al. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. J Infect Dis 1997;175:944-6.
15. Harrison CJ, Waner JL. Natural killer cell activity in infants and children excreting cytomegalovirus. J Infect Dis 1985;151:301-7.
16. Stites DP, Terr AI, Parslow TG. Medical immunology. 9th ed. Stamford, Conn.: Appleton & Lange, 1997.
17. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: John Wiley, 2000.
18. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003;289:1008-11.
19. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992;326:663-7.
20. Adler SP, Chandrika T, Lawrence L, Baggett J. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr Infect Dis 1983;2:114-8.
21. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infection in newborn infants. J Pediatr 1981;98:281-7.
22. Adler SP, Baggett J, Wilson M, Lawrence L, McVoy M. Molecular epidemiology of cytomegalovirus transmission in a nursery: lack of evidence for nosocomial transmission. J Pediatr 1986;108:117-23.
23. Bratcher DF, Bourne N, Bravo FJ, et al. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 1995;172:944-50.
24. Chatterjee A, Harrison CJ, Britt WJ, Bewtra C. Modification of maternal and congenital cytomegalovirus infection by antiglycoprotein b antibody transfer in guinea pigs. J Infect Dis 2001;183:1547-53.
25. Rook AH. Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988;10:Suppl 3:S460-S467.
26. Dokun AO, Kim S, Smith HR, Kang HS, Chu DT, Yokoyama WM. Specific and nonspecific NK cell activation during virus infection. Nat Immunol 2001;2:951-6.
27. Sissons JG, Carmichael AJ, McKinney N, Sinclair JH, Wills MR. Human cytomegalovirus and immunopathology. Springer Semin Immunopathol 2002;24:169-85.
28. Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR. From infection to autoimmunity. J Autoimmun 2001;16:175-86.
29. Adler SP. Cytomegalovirus and child daycare: evidence for an increased infection rate among caretakers. N Engl J Med 1989;321:1290-6.
30. Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein b and a new adjuvant. J Infect Dis 1999;180:970-5.
31. Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 1998;17:200-6.